tiprankstipranks
Trending News
More News >

Medicenna Unveils Groundbreaking Preclinical Therapy Results

Story Highlights
Medicenna Unveils Groundbreaking Preclinical Therapy Results

Medicenna Therapeutics Corp (TSE:MDNA) has released an update.

Confident Investing Starts Here:

Medicenna Therapeutics Corp has presented promising preclinical results for two novel treatments at the Promise of Interleukin-2 Therapy Conference. Their IL-2 Super-antagonist, MDNA209, shows potential in treating autoimmune diseases by significantly improving survival rates in a GvHD animal model. Meanwhile, their targeted BiSKIT therapy, MDNA113, exhibited enhanced efficacy in tumors overexpressing IL-13Rα2, offering hope for hard-to-treat cancers.

For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1